Flurbiprofen

Name	Flurbiprofen
Classes	Analgesic / Pain Killer Central Nervous System Agent NSAID Dermatological/Topical Agent Ophthalmic Preparation
Diseases	Arthritis Inflammatory Disease

Back

Bangla

English

Flurbiprofen is a member of the phenyl alkanoic acid derivative group of nonsteroidal anti-inflammatory drugs.

Flurbiprofen is indicated:

Carefully consider the potential benefits and risks of Flurbiprofen and other treatment options before deciding to use Flurbiprofen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.
After observing the response to initial therapy with Flurbiprofen, the dose and frequency should be adjusted to suit an individual patient’s needs.
For relief of the signs and symptoms of rheumatoid arthritis or osteoarthritis, the recommended starting dose of Flurbiprofen is 200 to 300 mg per day, divided for administration two, three, or four times a day. The largest recommended single dose in a multiple-dose daily regimen is 100 mg.

Side effects associated with flurbiprofen include-

Edema	Abdominal Pain	Diarrhea
Dyspepsia	Liver problems	Anxiety

Hypertension: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure.
Heart Failure and Edema: Avoid use of FLURBIPROFEN in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure.
Renal Toxicity: Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of FLURBIPROFEN in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function.
Anaphylactic Reactions: Seek emergency help if an anaphylactic reaction occurs.
Exacerbation of Asthma Related to Aspirin Sensitivity: FLURBIPROFEN is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity).
Serious Skin Reactions: Discontinue FLURBIPROFEN at first appearance of skin rash or other signs of hypersensitivity.
Premature Closure of Fetal Ductus Arteriosus: Avoid use in pregnant women starting at 30 weeks gestation.
Hematologic Toxicity: Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia.

FLURBIPROFEN Tablets are contraindicated in patients with known hypersensitivity to flurbiprofen or other similar drugs, such as-

None.

FLURBIPROFEN should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs. Severe, rarely fatal, anaphylactic-like reactions to nonsteroidal anti-inflammatory drugs have been reported in such patients.
Pregnant women of 30 weeks gestation.